OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
An annual survey on inspections and audits has revealed opportunities to use more flexible approaches to optimize processes.
May 24, 2022
AstraZeneca's recombinant COVID-19 vaccine, originally invented by the University of Oxford, has been approved as a third dose booster vaccine in the EU.
Investment has been made into a new science hub at the University of Edinburgh for the development of treatments for lung infections and future pandemics.
May 23, 2022
AstraZeneca has signed a license agreement with RQ Biotechnology for monoclonal antibodies to treat COVID-19.
May 18, 2022
Pfizer and BioNTech’s COVID-19 vaccine has been granted EUA for booster doses in children five through 11 years of age.
The companies have reached an agreement with the European Commission to update their COVID-19 vaccine supply agreement.
May 11, 2022
The drug is the first immunomodulatory COVID-19 treatment approved by FDA.
May 06, 2022
FDA is limiting the use of Janssen’s COVID-19 vaccine to certain individuals.
May 03, 2022
FDA’s Office of Compliance has released its 2021 Annual Report, which highlights the agency’s successes in public health.
May 02, 2022
Moderna has filed for emergency use authorization of its COVID-19 vaccine for use in young children six months to under six years of age.
What are the next steps for permanent authorization of COVID-19 vaccines, treatments, and diagnostics?